RT Journal Article
SR Electronic
T1 A Population-Based Cross-Sectional Investigation of COVID-19 Hospitalizations and Mortality Among Autistic People
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2024.02.23.24303274
DO 10.1101/2024.02.23.24303274
A1 Nijhof, Dewy
A1 Sosenko, Filip
A1 Mackay, Daniel
A1 Fleming, Michael
A1 Jani, Bhautesh D
A1 Pell, Jill
A1 Hatton, Chris
A1 Cairns, Deborah
A1 Henderson, Angela
A1 Ward, Laura
A1 Rydzewska, Ewelina
A1 Gardani, Maria
A1 Millington, Elliot
A1 Melville, Craig
A1 the CVD-COVID-UK/COVID-IMPACT Consortium
YR 2024
UL http://medrxiv.org/content/early/2024/02/24/2024.02.23.24303274.abstract
AB Background Current evidence suggests the possibility that autistic people may be at more risk of COVID-19 infection, hospitalisation, and mortality than the general population. Previous studies, however, are either limited in scale or do not investigate potential risk factors. Whilst many risk factors have been speculated to be responsible for severe COVID-19, this research has focused on general population samples.Methods Using data-linkage and a whole-country population, this study modelled associations between autism and COVID-19 hospitalisation and mortality risk in adults, investigating a multitude of clinical and demographic risk factors.Results Autistic adults had higher rates of hospitalisation, Standardised Incident Ratio 1.6 in 2020 and 1.3 in 2021, and mortality, Standardised Mortality Ratio 1.52 in 2020 and 1.34 in 2021, due to COVID-19 than the general population. In both populations, age, complex multimorbidity and vaccination status were the most significant predictors of COVID-19 hospitalisation and mortality. Effects of psychotropic medication varied by class.Conclusions Although similar factors exhibited a positive association with heightened risk of severe COVID-19 in both the autistic and general populations, with comparable effect sizes, mortality rates were elevated among the autistic population as compared to the general population. Specifically, the presence of complex multimorbidity and classification of prescribed medications may emerge as particularly significant predictors of severe COVID-19 among individuals within the autistic population due to higher prevalence of complex multimorbidity in the autistic population and variability in the association between medication classes and severe COVID-19 between both populations, though further research is needed.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThe British Heart Foundation Data Science Centre (grant No SP/19/3/34678, awarded to Health Data Research (HDR) UK) funded co-development (with NHS England) of the Secure Data Environment service for England, provision of linked datasets, data access, user software licences, computational usage, and data management and wrangling support, with additional contributions from the HDR UK Data and Connectivity component of the UK Government Chief Scientific Adviser's National Core Studies programme to coordinate national COVID-19 priority research. Consortium partner organisations funded the time of contributing data analysts, biostatisticians, epidemiologists, and clinicians. The associated costs of accessing data in NHS England's Secure Data Environment service for England, for analysts working on this study, were funded by the Data and Connectivity National Core Study, led by Health Data Research UK in partnership with the Office for National Statistics, which is funded by UK Research and Innovation (grant ref: MC_PC_20058). The Baily Thomas Charitable Fund funded staff (FS) time on this project.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The North-East-Newcastle and North Tyneside 2 research ethics committee provided ethical approval for the CVD-COVID-UK/COVID-IMPACT research programme (REC No 20/NE/0161) to access, within secure trusted research environments, unconsented, whole-population, de-identified data from electronic health records collected as part of patients' routine healthcare. The need for informed consent was waived by the North-East-Newcastle and North Tyneside 2 research ethics committee. All methods were carried out in accordance with relevant guidelines and regulations.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.Yes